Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment, which tends to impact boys more severely. Affected individuals usually have delayed development of speech and language by age 2.
A major obstacle in developing treatments for rare neurologic disorders and diseases like Fragile X is the lack of standardized measurements for these interventions, in part due to limited research. To help address this, Ovid Therapeutics assessed what been done in previous trials of Fragile X syndrome to establish a Visual Analog Scale, or VAS, to measure the impact of their candidate product.
To find out more about this, how it incorporates the patient and physician perspectives, and how it can be used in the process of bringing an option to a condition with no approved therapies, NeurologyLive spoke with Amit Rakhit, MD, MBA, chief medical officer, and head, Research & Development, Ovid Therapeutics, at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania.
